Hematologic malignancies in elderly patients.

Haematologica

Experimental Cancer Medicine (ECM), Clinical Research Centre (KFC), Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Stockholm

Published: July 2014

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4077070PMC
http://dx.doi.org/10.3324/haematol.2014.107557DOI Listing

Publication Analysis

Top Keywords

hematologic malignancies
4
malignancies elderly
4
elderly patients
4
hematologic
1
elderly
1
patients
1

Similar Publications

Background: Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment landscape for various hematological malignancies. However, it is associated with a range of hematologic complications, including severe and often prolonged thrombocytopenia. Currently, there are no known effective preventative or management measures against CAR-T-induced thrombocytopenia.

View Article and Find Full Text PDF

Background: Venous thromboembolism (VTE) and atrial fibrillation (AF) disproportionately affect older adults, who are at increased risk of bleeding from treatment with anticoagulant therapy. The impact of bleeding on older adults' quality of life (QoL) is poorly understood due to the lack of a validated measure of their experience. This study's purpose is to describe the first evidence-based steps in developing a new condition-specific patient-reported outcome measure (PROM) for the effect of anticoagulant-related bleeding on older adults' QoL.

View Article and Find Full Text PDF

Potentially paraneoplastic glomerulopathies in a Brazilian cohort: a retrospective analysis.

J Bras Nefrol

January 2025

Universidade Federal de São Paulo (UNIFESP), Departamento de Medicina, Divisão de Nefrologia, São Paulo, SP, Brazil.

Introduction: Glomerular diseases can be associated with solid or hematopoietic malignancies. The prevalence of these associations varies according to the studied glomerular disease. This study aimed to evaluate the frequency and type of neoplasms in patients with glomerular diseases as well as their clinical, laboratory, and histopathological features and the relationship with immunosuppressive therapy.

View Article and Find Full Text PDF

Sodium valproate enhances efficacy of NKG2D CAR-T cells against glioblastoma.

Front Immunol

January 2025

Guangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.

Chimeric antigen receptor T-cell (CAR-T) therapies have shown promise in glioblastoma clinical studies, but responses remain inconsistent due to heterogeneous tumor antigen expression and immune evasion post-treatment. NKG2D CAR-T cells have demonstrated a favorable safety profile in patients with hematologic tumors, and showed robust antitumor efficacy in various xenograft models, including glioblastoma. However, malignant glioma cells evade immunological surveillance by reducing NKG2D ligands expression or cleavage.

View Article and Find Full Text PDF

Case reports of Strongyloides stercoralis infection in three patients with haematological malignancies.

Trop Biomed

December 2024

Department of Medical Microbiology & Parasitology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Malaysia.

Strongyloidiasis is a parasitic nematode infection mainly caused by Strongyloides stercoralis. Immunocompromised conditions, particularly cancer patients treated with chemotherapy and corticosteroids, have a significant risk of developing Strongyloides hyperinfection. The lack of a gold standard laboratory method to rule out this infection and the insensitivity of microscopic stool examination due to low and intermittent larvae output in stool contribute to the low detection rate of this infection.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!